JAC Advance Access originally published online on March 20, 2008
Journal of Antimicrobial Chemotherapy 2008 61(6):1393-1394; doi:10.1093/jac/dkn109
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Research letters |
High prevalence of CTX-M-15-producing Klebsiella pneumoniae among inpatients and outpatients with urinary tract infection in Southern India
1 Department of Microbiology, Gulbarga University, Karnataka, India 2 Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, PA, USA 3 University of Queensland, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
* Corresponding author. Tel: +1-412-648-6401; Fax: +1-412-648-6399; E-mail: doiy{at}dom.pitt.edu
Keywords: Enterobacteriaceae , antimicrobial resistance , resistance mechanisms , β-lactams
The population of India of over one billion represents a potentially vast reservoir of antimicrobial resistance genes including those encoding extended-spectrum β-lactamases (ESBLs). Occurrence of ESBL-producing Enterobacteriaceae has been described in India mostly using phenotypic detection methods alone. The present study was conducted to identify the occurrence of ESBL genes in urinary isolates of Klebsiella pneumoniae collected in Southern India.
The study was conducted at two hospitals, one in Gulbarga and the other in Raichur, between July 2005 and March 2006. The two cities are ~150 km away from each other and have populations of ~440 000 and 160 000, respectively. A total of 1288 non-duplicate urine specimens were collected from 642 inpatients and 646 outpatients. K. pneumoniae was identified by standard biochemical tests including citrate, urease, indole, Voges–Proskauer, glucose and inositol. As a result, K. pneumoniae was recovered from 270 of 1288 urinary specimens. Among them, 115 (43%) were from inpatients and 155 (57%) were from outpatients. ESBL production was confirmed in 260 (96%) isolates using the disc method defined by the CLSI (2007). All these isolates produced 
5 mm increase in zone diameters with either cefotaxime or ceftazidime discs when clavulanic acid was added. They represented 95% and 97% of the inpatient and outpatient isolates, respectively. Of those, 255 isolates were resistant to cefotaxime and were assigned to phenotypic Group I, which was further classified into subgroups depending on susceptibility to ceftazidime and cefepime (Table 1). Another five isolates with resistance to ceftazidime but not to cefotaxime were assigned to phenotypic Group II. The remaining 10 non-ESBL-producing isolates susceptible to both cefotaxime and ceftazidime were assigned to phenotypic Group III. For non-β-lactam antimicrobials, 92% and 95% of the inpatient and outpatient isolates were resistant to ciprofloxacin, respectively. High rates of resistance to gentamicin (79% and 83% in inpatient and outpatient isolates, respectively) and amikacin (66% and 69% in inpatient and outpatient isolates, respectively) were also observed. Resistance to chloramphenicol, which is still commonly prescribed for infections caused by K. pneumoniae in India, was observed in 90% and 92% of the inpatient and outpatient isolates, respectively. All the study isolates were susceptible to ertapenem, except for one isolate which was intermediately resistant. No resistance to imipenem was identified.
|
A total of 35 isolates from all phenotypic groups and subgroups were subjected to PFGE analysis using restriction enzyme XbaI (New England Biolabs, Ipswich, MA, USA) and CHEF III DR electrophoresis system (Bio-Rad, Hercules, CA, USA). Forty-five percent of the isolates in the phenotypic Group I that were examined by PFGE belonged to pulsotype A (Table 1). This pulsotype was commonly observed regardless of the source hospitals or the patient locations. The isolates in the phenotypic Group II belonged to pulsotype D. A total of 60 isolates from various pulsotypes were then subjected to PCR analysis for the detection of blaTEM, blaSHV and blaCTX-M, as described previously.1,2 All the isolates belonging to the phenotypic Group I yielded amplicons consistent with blaCTX-M. The gene was confirmed as blaCTX-M-15 in representative isolates by sequencing the entire open-reading frame using the following external primers: CTX-M-15-SF, 5'-CACACGTGGAATTTAGGGACT-3' and CTX-M-15-SR, 5'-GCCGTCTAAGGCGATAAACA-3'. These results were consistent with the findings in a previous study reporting the predominance of blaCTX-M-15 in a small number of isolates from Southern India.3 Some of the Group I isolates were positive for blaTEM or blaSHV. The sequences of representative amplicons were consistent with blaTEM-1 and either blaSHV-1 or blaSHV-28, respectively, all of which are non-ESBL genes. All five isolates in Group II were positive for blaSHV-12, an ESBL gene, and negative for blaTEM or blaCTX-M.
The prevalence of ESBL producers in this study was strikingly high, particularly given the fact that more than half of the isolates were obtained from outpatients. One of the reasons contributing to the high prevalence of ESBL may be the crowded hospital conditions precluding implementation of optimal hygiene practices. The epidemic in the community is then likely fuelled by unrestricted use of antimicrobials that may be purchased without prescription.4 A recent study reported that ESBL-producing Enterobacteriaceae, including K. pneumoniae, were responsible for community-onset infections in India.5 Dissemination of ESBL-producing K. pneumoniae in the community has a serious implication in the empirical management of complicated urinary tract infections caused by this organism, given their tendency for co-resistance to non-β-lactam classes of antimicrobials, as was observed in the present study. CTX-M-15 is known to be an ESBL that has peculiar association with community-onset Escherichia coli infections.6 It may therefore be speculated that CTX-M-15-producing E. coli is already established in the community in this area and that the responsible gene is being exchanged between E. coli and K. pneumoniae by means of conjugal transfer, both in the healthcare and in the community environments.
 |
Funding |
|---|
 Top Funding Transparency declarationsReferences |
|---|
D. L. P. is supported in part by NIH grant R01AI070896. Y. D. is supported by NIH grant T32AI007333.
|
Transparency declarations |
|---|
|
TopFundingTransparency declarationsReferences |
|---|
None to declare.
|
References |
|---|
|
TopFundingTransparency declarationsReferences |
|---|
1 Kruger T, Szabo D, Keddy KH, et al. Infections with nontyphoidal Salmonella species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa. Antimicrob Agents Chemother (2004) 48:4263–70.
2
Edelstein M, Pimkin M, Palagin I, et al. Prevalence and molecular epidemiology of CTX-M extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals. Antimicrob Agents Chemother (2003) 47:3724–32.
3
Ensor VM, Shahid M, Evans JT, et al. Occurrence, prevalence and genetic environment of CTX-M β-lactamases in Enterobacteriaceae from Indian hospitals. J Antimicrob Chemother (2006) 58:1260–3.
4 Ray K, Mukhopadhyay S, Dutt D, et al. Cross-sectional study of consumption, compliance and awareness about antibiotic utilisation amongst the urban community in Kolkata. J Indian Med Assoc (2003) 101:9–10. 7.
5 Gupta V, Datta P. Extended-spectrum β-lactamases (ESBL) in community isolates from North India: frequency and predisposing factors. Int J Infect Dis (2007) 11:88–9.[CrossRef][Web of Science][Medline]
6
Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother (2008) 61:273–81.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. E. Sidjabat, D. L. Paterson, J. M. Adams-Haduch, L. Ewan, A. W. Pasculle, C. A. Muto, G.-B. Tian, and Y. Doi Molecular Epidemiology of CTX-M-Producing Escherichia coli Isolates at a Tertiary Medical Center in Western Pennsylvania Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4733 - 4739. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||